Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Helsinn Healthcare SA clinical trials
The registry lists 42 studies whose lead sponsor is Helsinn Healthcare SA or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 6, 2026.
Keep track of what changes. Save the Helsinn Healthcare SA studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Helsinn Healthcare SA.
- Helsinn Healthcare SA32 studiesSame company
Something wrong?
- Helsinn Therapeutics (U.S.), Inc10 studies →Acquired
Something wrong?
Focus areas
Conditions Helsinn Healthcare SA leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)RecruitingNCT06904235Phase 2
- A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2CompletedNCT03743064Phase 3
- A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1CompletedNCT03743051Phase 3
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)CompletedNCT04817189Phase 4
- A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy VolunteersTerminatedNCT06840769Phase 1
- PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and VomitingCompletedNCT03204279Phase 2
- Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)CompletedNCT02383810Phase 2
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsWithdrawnNCT05222165Phase 1/2
- An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid LeukemiaTerminatedNCT03151408Phase 3
- A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic SyndromesTerminatedNCT03151304Phase 2
- An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01363479Phase 3
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01912274Phase 2
- Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®CompletedNCT03255980Not applicable
- A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerCompletedNCT03403712Phase 3
- Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell LymphomaCompletedNCT02296164
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck CancerTerminatedNCT03601962Not applicable
- A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The BodyCompletedNCT03495934Phase 1
- Effects of Somnage® in the Management on Sleep and Mood in Cancer PatientsTerminatedNCT02883790Not applicable
- Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic SyndromeCompletedNCT01873703Phase 2
- An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and VomitingCompletedNCT02557035Phase 3
- A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and VomitingCompletedNCT02517021Phase 3
- Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)CompletedNCT01387282Phase 3
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)CompletedNCT01387269Phase 3
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)CompletedNCT01395914Phase 3
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusCompletedNCT00672074Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Dose Range Study of Anamorelin in Patients With Non-small Cell Lung CancerCompletedNCT00622193Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionCompletedNCT01280344Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMACompletedNCT01993641Phase 2
- Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult SubjectsCompletedNCT02058784Early Phase 1
- Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking SubjectsCompletedNCT02118909Phase 1
- Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung CancerWithdrawnNCT02877966Not applicable
- Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic TherapyCompletedNCT01887314Not applicable
- Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT00828295Phase 3
- An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01339260Phase 3
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01376297Phase 3
- Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric PatientsCompletedNCT01442376Phase 3
- Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT01395901Phase 3
- Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced DiarrheaCompletedNCT01543451Phase 2
- Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/CachexiaCompletedNCT00378131Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.CompletedNCT00267358Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight LossCompletedNCT00219817Phase 2
Sponsor listed in the registry: Helsinn Therapeutics (U.S.), Inc · Helsinn Therapeutics (U.S.), Inc — acquired company within the Helsinn Healthcare SA group
- XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary TumorsTerminatedNCT00090025Phase 3